Retinal pigment epithelial cell manufacturing technique ready for Phase I clinical trials
A collaborative team from the National Institute of Health and the National Eye Institute (both MD, USA) has developed a novel GMP compliant manufacturing process for iPSC-derived retinal pigment epithelial cells, as a potential treatment opportunity for age-related macular degeneration.
Please sign in or register for FREE
Sign in to RegMedNet
Not yet a member? Become a member FREE to:
- Get unlimited access to ALL CONTENT
- Read selected articles from journals such as Regenerative Medicine FREE
- Receive a weekly email roundup of the latest news and expert opinions
Did you know?
Your RegMedNet account also gives you access to communities on drug discovery, real-world evidence and 3D printing in medicine. Find out more>>